MeiraGTx Holdings PLC (MGTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MeiraGTx Holdings PLC (MGTX) has a cash flow conversion efficiency ratio of -0.179x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-38.54 Million) by net assets ($215.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see MGTX market cap for the company's overall valuation and market capitalisation.
MeiraGTx Holdings PLC - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how MeiraGTx Holdings PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
MeiraGTx Holdings PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MeiraGTx Holdings PLC ranked by their cash flow conversion efficiency. Explore MeiraGTx Holdings PLC (MGTX) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jastrzebska Spotka Weglowa SA
WAR:JSW
|
-0.112x |
|
Shenzhen Laibao High-Technology Co Ltd
SHE:002106
|
0.017x |
|
Preferred Bank
NASDAQ:PFBC
|
0.036x |
|
Alexander & Baldwin Inc
F:ABU
|
0.024x |
|
Birchcliff Energy Ltd.
TO:BIR
|
0.042x |
|
Chengdu Leejun Industrial Co Ltd
SHE:002651
|
0.000x |
|
Lapidoth
TA:LAPD
|
0.028x |
|
JiShi Media Co Ltd
SHG:601929
|
0.025x |
Annual Cash Flow Conversion Efficiency for MeiraGTx Holdings PLC (2016–2025)
The table below shows the annual cash flow conversion efficiency of MeiraGTx Holdings PLC from 2016 to 2025. View MeiraGTx Holdings PLC stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-5.79 Million | $-46.36 Million | 8.003x | +619.44% |
| 2024-12-31 | $67.83 Million | $-104.50 Million | -1.541x | -102.04% |
| 2023-12-31 | $138.18 Million | $-105.36 Million | -0.763x | -22.82% |
| 2022-12-31 | $117.74 Million | $-73.10 Million | -0.621x | -993.13% |
| 2021-12-31 | $185.40 Million | $-10.53 Million | -0.057x | +78.82% |
| 2020-12-31 | $238.56 Million | $-63.97 Million | -0.268x | -355.23% |
| 2019-12-31 | $190.80 Million | $20.04 Million | 0.105x | +114.46% |
| 2018-12-31 | $81.06 Million | $-58.89 Million | -0.726x | -290.58% |
| 2017-12-31 | $-47.37 Million | $-18.06 Million | 0.381x | -54.53% |
| 2016-12-31 | $-17.14 Million | $-14.37 Million | 0.838x | -- |
About MeiraGTx Holdings PLC
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xe… Read more